The effect of hypertension on the expression of a fatty acid binding protein localized in the rat aorta was studied. The presence of rat heart fatty acid binding protein (hFABP) was documented in aortic tissue by using a cJDNA probe and polyclonal antibodies. Hypertension was induced in groups of rats by implantation of deoxycorticosterone acetate in conlunction with 1% salt in the drinking water (deoxycorticosterone/salt). By the third week of this treatment a marked reduction (by a factor of 20) in the expression of hFABP mRNA in aorta was found, concomitant with a reduction in immunologically detectable protein, suggesting transcriptional regulation. This effect was tissue specific, since no change in the normal amounts of hFABP mRNA in heart, skeletal muscle, or kidney was found. This reduction in aortic hFABP mRNA was also found in mildly hypertensive uninephrectomized rats given salt but no deoxycorticosterone and in normotensive rats given deoxycorticosterone but no excess 'salt intake. A marked decrease in aortic hFABP mRNA also was observed in the Goldblatt two kidney-one clip hypertensive model, and administration of angiotensin Il for 6 days by osmotic minipump also caused a reduction. These Findings suggest that hFABP is under complex regulation in aortic tissue and is suppressed by arterial hypertension.
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Hypertension is an important risk factor for all cardiovascular diseases, including stroke, myocardial infarction, peripheral vascular disease, and sudden death (1) . However, relatively little information is available on the nature of the cellular responses to hypertension in the arterial wall and the biochemical mechanisms mediating those responses. In the aorta, hypertension has been shown to induce alterations in connective tissue metabolism (2) , lysosomal enzymes (3),'ion transport (4) , and fuel metabolism (5, 6) . A variety of morphologic changes involving cellular components and extracellular matrix also have been described (7) (8) (9) . A consistent cellular change has been an increase in medial smooth muscle cell mass, which, depending on the animal model used or the rate of onset and severity of hypertension, has been associated with either smooth muscle cell hyperplasia, hypertrophy, or polyploidy (10) (11) (12) . With the exception of a recent study showing an increase in elastin mRNA in pulmonary arteries of calves with pulmonary hypertension (13) , there have been no published papers on gene expression in vascular tissue obtained directly from hypertensive animal models.
We previously reported the characteristics of a fatty acid binding protein (FABP) in rat heart (14-16). In the current work, we have identified this protein in rat aorta and studied the influence of different forms of hypertension on its expression. Heart fatty acid binding protein (hFABP) is one member ofa multigene family ofintracellular proteins located in the cytosol that specifically bind fatty acids, retinol, and several other organic anions (17, 18) . The function of hFABP is presumed to facilitate the uptake and intracellular metabolism of long-chain fatty acids, but definitive experiments establishing the function of any of the FABPs have not yet been reported. However, recent studies have implicated these proteins in the regulation of cell growth and differentiation (19) (20) (21) .
Several FABPs have been cloned (16, (22) (23) (24) and changes in gene expression have been studied, particularly with respect to development. There has been no reported change in the mRNA or protein levels of hFABP in any pathophysiological state in animal models. In the present study we have documented the presence of hFABP in aorta and demonstrated that decreased expression of this gene in the vessel wall appears to be characteristic of the hypertensive state. (25) . Essentially, 9- (16) . The rat actin cDNA [1.2 kilobases (kb)] also has been described (29) . After hybridization, membranes were washed three times for 20 min at 60°C using increasing stringency with 1% NaDodSO4 and 0.15 M NaCl/0.15 M sodium citrate, 75 mM NaCl/7.5 mM sodium citrate, and 30 mM NaCl/3 mM sodium citrate, respectively. Blots were then exposed to a preflashed x-ray film (Kodak X-Omat) for 2-8 hr at -70°C. When indicated, films were scanned by laser densitometry. Protein Isolation and Analysis. Aortas from either control or treated rats were rinsed in cold phosphate-buffered saline (PBS) and frozen in liquid nitrogen. The frozen tissue was pulverized with a mortar and pestle and homogenized with a Brinkmann Polytron in 10 vol of 30 mM Tris-HCl, pH 7.5/ 0.12 M NaCl/0.001% (wt/vol) phenylmethylsulfonyl fluoride. All of the following procedures were performed at 4°C. The homogenates were centrifuged at 18,000 x g for 20 min and the resulting supernatant was centrifuged at 150,000 x g for 90 min. The high-speed supernatant (cytosol fraction) was analyzed for protein concentration using the bicinchoninic acid (BCA) reagent (Pierce). Cytosol fractions from control or treated tissues either were used directly for NaDod-S04/PAGE or were fractionated by Sephadex G-75 chromatography.
MATERIALS AND METHODS
Gel filtration. Sephadex G-75 chromatography was performed by using a 1.5 x 70 cm column equilibrated in 30 mM Tris HCl (pH 7.5) at 4°C. Eluant fractions were collected and analyzed for absorbance at 280 nm. Fractions containing low molecular mass proteins [12-20 kDa, Ve = 75-87 ml (Kav= 0.41)] were pooled and concentrated using an Amicon YM2 ultrafiltration membrane.
Protein electrophoresis and immunoblotting. NaDodSO4/ PAGE of protein extracts were performed as described by Laemmli (30) with 15% bisacrylamnide gels. Electrophoretic (Western) blot transfer onto nitrocellulose was carried out in a Trans-Blot cell (Bio-Rad). Immunological detection was performed with rabbit monospecific polyclonal anti-rat hFAB3P antibodies as described (15) . phrectomy and deoxycorticosterone/salt treatment on hFABP mRNA. The hFABP mRNA in aorta is the same size (0.85 kb) as that in the heart and appears to be relatively abundant. Densitometry performed on four separate aortic RNA preparations obtained from 12 control rats compared to RNA from control hearts indicated that aortic tissue contained about 15% of the hFABP mRNA found in heart. The RNA preparations were of uniform quantity and quality. Fig.  1 Lower shows that when the same Northern blot was hybridized with a rat actin probe, no change in actin mRNA was obvious in the aortic samples.
Control rats that were uninephrectomized, but not given deoxycorticosterone or salt for up to 5 weeks, had no major change in the amount of hFABP mRNA (Fig. 1, lanes 1-3) , nor was there any change for up to 2 weeks of treatment with deoxycorticosterone/salt (Fig. 1, lanes 4-6) . However, an abrupt decrease in expression was observed between 2 and 3 weeks of treatment (Fig. 1, lanes 6 and 7) . The decrease in mRNA for hFABP found by the third week of treatment (Fig.  1, lane 7) was a consistent observation and was also demonstrated in three other pooled samples of aorta obtained from a total of 12 rats treated for 3 weeks. It was between 2 and 3 weeks that the greatest increase in blood pressure and cardiac hypertrophy were observed ( Table 1 ). The decrease in hFABP mRNA persisted through the fourth week of treatment, as shown in Fig. 1, lanes 8-10 , which contain three separate pooled samples of aorta from animals killed 4 weeks following the deoxycorticosterone implant. Densitometric analysis comparing aortic samples from uninephrectomized controls and rats treated with deoxycorticosterone/salt for 3-4 weeks indicated that hFABP mRNA was decreased by a factor of -20 to values ranging between 3% and 7% of normotensive controls.
Additional information on hFABP mRNA expression in the deoxycorticosterone/salt model is shown in Fig. 2 . Northern blot analysis using hFABP cDNA as the probe of aortic RNA from rats treated as specified for 3 weeks is shown in Fig. 2 Upper. Lanes 1 and 2 are from untreated rats with both kidneys intact and untreated uninephrectomized rats, respectively, and show that uninephrectomy alone does not alter expression ofhFABP MnRNA. Decreased expression of hFABP was seen when uninephrectomized rats were given salt in their drinking water, without deoxycorticosterone administration (Fig. 2, lane 3) ; these animals had a mild elevation of blood pressure to average systolic levels of 154 mmHg (Table 1) . When uninephrectomized rats were given deoxycorticosterone and fed a low-salt diet without salt in the drinking water, no increase in blood pressure was observed. However, a decrease in hFABP mRNA was detected after 3 weeks of treatment (Fig. 2, lane 4) , but the change was less marked than that seen with saline treatment. Fig. 2 , lane 5, contained RNA from a group of uninephrectomized, deoxycorticosterone/salt-treated hypertensive rats distinct from that shown in Fig. 1 and indicates an almost complete suppression of hFABP mRNA in aorta. The blot shown is relatively overexposed to emphasize the decreases seen in lanes 3 and 5. In separate experiments we have established that for rats treated with deoxycorticosterone and given a low or normal salt intake, decreases in hFABP mRNA averaged about 20%o of control levels. In contrast to the effects of deoxycorticosterone/salt treatment in aortic tissue, no changes in hFABP mRNA levels were observed in heart, skeletal muscle, or kidney from deoxycorticosterone/salt-treated rats throughout a 3-week treatment period (Fig. 2 Lower). During this time the heart undergoes hypertension-induced hypertrophy, and by 4 weeks the heart weight/body weight ratio increased signifi- cantly over control values ( Table 1 ). The tissue specificity of the deoxycorticosterone/salt-induced change in hFABP mRNA was further emphasized by the absence of any detectable change in hFABP mRNA levels either in red skeletal muscle or kidney, tissues that were shown previously to express hFABP (16) . The deoxycorticosterone/salt model requires uninephrectomy, and the contralateral kidney undergoes a striking hypertrophic response, even greater than the hypertrophy characteristically occurring following uninephrectomy alone. In animals of the same age, average kidney weights for normal kidney or the contralateral kidney 21 days following either uninephrectomy alone or uninephrectomy and deoxycorticosterone/salt treatment were 1.7 g, 2.6 g, and 3.1 g, respectively. Despite the pronounced hypertrophy occurring in heart and kidney, only the aorta showed a decrease in hFABP mRNA.
Deoxycorticosterone/salt-induced hypertension also produced a concomitant decrease in hFABP protein in aortic tissue. Fig. 3 shows the presence of immunoreactive hFABP in the cytosol of aorta from untreated rats and the decrease following 3 weeks of deoxycorticosterone/salt treatment. The cytosol fractions were fractionated by NaDodSO4/ PAGE, and immunoreactive hFABP was detected on a Western blot using polyclonal antibodies against rat hFABP. A well-defined immunoreactive protein was present at about 14-15 kDa in control tissue, and a marked decrease in immunoreactive protein was seen in the lane containing aortic protein from hypertensive rats (Fig. 3A) . Aortic cytosol from control and hypertensive rats also was applied onto a Sephadex G-75 column, and Western blots were analyzed on pooled and concentrated fractions following gel filtration (Fig. 3B) . hFABP was detected in the fractions normally containing proteins between 20 and 11 kDa, and, after electrophoresis, the immunoreactive protein had a size identical to purified hFABP from rat heart. Although detectable protein was found in aortic tissue from deoxycorticosterone/ salt treated animals, it was less than that in control aortic tissue. Thus, deoxycorticosterone/salt treatment caused a reduction in aortic hFABP mRNA and the corresponding protein.
To determine if the decrease in expression of hFABP mRNA was a general response to hypertension, two additional experimental models were tested (Fig. 4) . Renin-dependent renovascular hypertension produced by clipping one Medical Sciences: Sarzani et al. II for 6 days, also led to decreased hFABP mRNA when compared to sham-treated animals (Fig. 4) .
DISCUSSION
In this study we have shown that rat hFABP is expressed in rat aorta, thereby extending the known tissue distribution of hFABP to include vascular tissue. Furthermore, we have found that hFABP mRNA expression in aortic tissue from three different hypertensive animal models is strongly suppressed, this effect being the most pronounced change in vascular gene expression yet described in response to hypertension. In at least one of these hypertensive models, a reduction in the protein also was measured. The possible difference in the extent of the reduction observed between protein and mRNA could be due to a slower turnover of the protein. This effect of hypertension was tissue specific since, in deoxycorticosterone/salt-treated animals, the amounts of hFABP mRNA normally present in heart, muscle, and kidney did not change. One characteristic response of the aorta to hypertension is hypertrophy, but it seems unlikely that the decrease in hFABP would be causally linked to a hypertrophic response. In the deoxycorticosterone/salt and twokidney, one-clip models of hypertension, heart and kidney undergo even greater hypertrophy than aorta, yet no change in hFABP expression was noted in those organs.
Mechanical effects of increased pressure have been suggested to influence the vessel wall, and several studies performed in vivo or with cultured endothelial and smooth muscle cells have demonstrated biochemical and morphologic changes in response to different condition of flow (9, 31) . Arteries are exposed to higher pressure and shear stress than other tissues, and it is conceivable that mechanical effects alone could promote intracellular signals that lead to changes in hFABP gene expression. Mecham et al. (13) recently showed a change in elastin mRNA expression in the pulmonary vasculature of newborn calves with induced pulmonary hypertension. They proposed that this effect is due to a substance made by smooth muscle cells that acts on the adventitia.
The use of disparate experimental models of hypertension permits some consideration of the possible mechanisms responsible for suppression of hFABP gene expression. The renin/angiotensin/mineralocorticoid system is known to be involved in regulation of blood pressure and water and salt balance (32) . Components of the system could influence hFABP gene expression by possibly acting directly through specific receptors present in the vessel wall or indirectly through alterations in ion transport. Angiotensin II clearly caused reduced expression of hFABP mRNA when it was infused at doses adequate to increase blood pressure. However, in the deoxycorticosterone/salt model, angiotensin II levels are very low and thus unlikely to mediate a direct effect. A direct role of deoxycorticosterone is not likely to be the sole or the major factor influencing hFABP, since a large reduction in hFABP mRNA was seen in uninephrectomized rats given 1% salt without deoxycorticosterone, a condition found to elevate blood pressure somewhat and to suppress the renin/angiotensin system and mineralocorticoid hormone production.
A likely common factor of each hypertensive model used for these studies is a change in ion transport. With the deoxycorticosterone/salt model, changes in arterial ion transport have been described even before hypertension is induced (33) , and alterations in plasma volume and electrolyte composition occur. Mineralocorticoids have been reported to increase directly the transport of sodium in tail arteries (34) . Angiotensin II has been shown to act directly on cultured vascular smooth muscle cells to induce changes in intracellular calcium and in Na+/H+ exchange (35, 36) .
Explanations for the enhanced vascular reactivity associated with vessels from hypertensive animals have attributed a causative role to increased intracellular free calcium, secondary perhaps to changes in sodium transport (37) . It is therefore possible that altered intracellular levels of either Na', Ca2 +, or other ions implicated in hypertension could act as intracellular regulators of hFABP expression.
The functional role of hFABP in aorta and the physiological significance of the decrease observed in hypertension is not clear, but its presence may imply a more important role for fatty acid utilization in vascular tissue than has been generally accepted. FABPs are abundant and present in tissues that utilize fatty acids, such as heart, muscle, liver, intestine, and adipose tissue, but each organ tends to contain a unique member of this multigene family. Earlier studies measuring the tissue distribution of hFABP in the rat showed it to be most abundant in heart muscle, comprising between 5% and 10% of the soluble protein in heart cytosol and suggesting, but not establishing, a functional role for this protein in uptake or utilization of long-chain fatty acids as a fuel source (15, 16, 22) .
It is possible that hFABP could be involved in cellular events other than fatty acid metabolism. A cellular retinoic acid binding protein, known to be in the same multigene family as hFABP, might have a role in delivering retinoic acid to a nuclear acceptor with properties analogous to those of steroid hormone receptors (38) . Also, a recent study identified a polypeptide growth inhibitor from bovine mammary gland that had an extensive sequence homology (84%) to rat hFABP (19) . This protein inhibited growth of mammary carcinoma or Ehrlich ascites carcinoma cells at concentrations of 1 nM, suggesting that hFABP, or a very similar polypeptide, could influence cell growth. Although there are presently no data that would implicate an autocrine or paracrine regulatory role for hFABP in the vessel wall, such regulation is currently an important area for study and it will be of obvious interest to determine the cellular localization of hFABP in the aorta and the biochemical events dependent upon its expression.
